Search Results for "Infection"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Infection. Results 611 to 620 of 842 total matches.

The Cervical Cap

   
The Medical Letter on Drugs and Therapeutics • Oct 07, 1988  (Issue 776)
the cap complained of pain during intercourse, and a higher percentage became infected with Gardnerella ...
The US Food and Drug Administration recently approved the marketing of a cervical cap (Prentif Cavity-Rim Cervical Cap - Lamberts Ltd, England), a contraceptive device that has been used in one form or another for many years (JP Koch, Contraception, 25:161, 1982). The cap is being distributed in the USA and Canada by Cervical Cap (CxC), Ltd, PO Box 38003-292, Los Gatos, CA 95031, telephone 408-358-6264; the distributor will make the caps available only to practitioners who have attended training seminars.
Med Lett Drugs Ther. 1988 Oct 7;30(776):93-4 |  Show IntroductionHide Introduction

Pentostatin and 2-Chlorodeoxyadenosine for Hairy-Cell Leukemia

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 1992  (Issue 879)
can last for years, but no increase in life-threatening opportunistic infections has been reported ...
Pentostatin (2'-deoxycoformycin; DCF; - Parke-Davis), a purine analog, was recently approved by the US Food and Drug Administration (FDA) for treatment of hairy-cell leukemia resistant to interferon alfa (Intron A; Roferon-A). is a rare (500 cases/year in the USA) form of chronic lymphocytic leukemia. Acutely ill patients may respond rapidly to interferon, but the drug is rarely curative. Another purine analog, 2-chlorodeoxyadenosine (CdA; Leustatin - Ortho Biotech), may also be approved soon for treatment of hairy-cell leukemia (JD Piro, Blood, 79:843, 1992). Fludarabine (Fludara...
Med Lett Drugs Ther. 1992 Sep 18;34(879):89-90 |  Show IntroductionHide Introduction

Recombinant Human Growth Hormone

   
The Medical Letter on Drugs and Therapeutics • Sep 02, 1994  (Issue 930)
Creutzfeldt-Jakob disease, a lethal prion infection (Medical Letter, 27:57, 1985). Recombinant DNA technology ...
Growth hormone has been in the news recently because of accusations of criminal misconduct in some marketing and prescribing practices (G Kolata, New York Times, August 15, 1994, page 1). The high cost of the drug and its widespread use for unauthorized indications apparently were contributing factors.
Med Lett Drugs Ther. 1994 Sep 2;36(930):77-8 |  Show IntroductionHide Introduction

The Prostatron: Microwaves for Benign Prostatic Hyperplasia

   
The Medical Letter on Drugs and Therapeutics • Jun 07, 1996  (Issue 976)
patients need additional treatment, either with the Prostatron or an alternative. Urinary tract infections ...
The Prostatron, a microwave device manufactured by EDAP Technomed in Cambridge, MA, has been approved by the US Food and Drug Administration for treating symptoms of benign prostatic hyperplasia (BPH).
Med Lett Drugs Ther. 1996 Jun 7;38(976):53-4 |  Show IntroductionHide Introduction

Tizanidine for Spasticity

   
The Medical Letter on Drugs and Therapeutics • Jul 04, 1997  (Issue 1004)
; these devices require meticulous care to avoid infection, and fatalities have occurred due to overdosage ...
Tizanidine (Zanaflex - Athena Neurosciences) has been approved by the US Food and Drug Administration for oral treatment of increased muscle tone associated with spasticity. It has been available in Europe and Japan for 12 years as a short-term muscle relaxant.
Med Lett Drugs Ther. 1997 Jul 4;39(1004):62-3 |  Show IntroductionHide Introduction

Rituximab for Non-Hodgkins Lymphoma

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 1998  (Issue 1029)
and bone marrow of B cells, no increase in infections has been reported. DOSAGE AND COST ...
Rituximab (Rituxan - IDEC Pharmaceutical/Genentech), a monoclonal antibody, has been approved by the FDA for treatment of low-grade B-cell non-Hodgkin's lymphoma. Most low-grade lymphomas are B-cell lymphomas.
Med Lett Drugs Ther. 1998 Jun 19;40(1029):65-6 |  Show IntroductionHide Introduction

New Monoclonal Antibodies to Prevent Transplant Rejection

   
The Medical Letter on Drugs and Therapeutics • Sep 25, 1998  (Issue 1036)
of opportunistic infection or, after one year, malignant disease has been detected with either drug. Muromonab-CD3 ...
Basiliximab (Simulect - Novartis) and daclizumab (Zenapax - Roche), two mouse/human monoclonal antibodies that block the interleukin-2 (IL-2) receptor on Tlymphocytes, have been approved by the FDA for use in the prevention of acute renal transplant rejection. Both drugs are used with cyclosporine (Sandimmune; Neoral) and corticosteroids. An all-murine anti-CD3 monoclonal antibody, muromonab-CD3 (Orthoclone OKT3), has been available in the USA for many years for treatment of transplant rejection, and has also been used with some success for prophylaxis (MI Wilde and KL Goa, Drugs,...
Med Lett Drugs Ther. 1998 Sep 25;40(1036):93-4 |  Show IntroductionHide Introduction

Malathion for the Treatment of Head Lice

   
The Medical Letter on Drugs and Therapeutics • Aug 13, 1999  (Issue 1059)
but is not ovicidal (TA Bell, Pediatr Infect Dis J, 17:923, 1998). TOXICOLOGY — Malathion is an irreversible ...
0.5% malathion in 78% isopropanol was recently approved by the FDA for treatment of head lice.
Med Lett Drugs Ther. 1999 Aug 13;41(1059):73-4 |  Show IntroductionHide Introduction

Cevimeline (Evoxac) For Dry Mouth

   
The Medical Letter on Drugs and Therapeutics • Aug 07, 2000  (Issue 1084)
coverage. XEROSTOMIA — Oral dryness can cause pain, mouth infections, dental caries, and difficulty ...
Cevimeline hydrochloride, an acetylcholine derivative, has been approved by the FDA for treatment of dry mouth symptoms caused by Sjogren's syndrome. Presumably it could also be used to treat radiation-induced xerostomia in patients with head and neck cancer. Pilocarpine hydrochloride is FDA-approved for both indications
Med Lett Drugs Ther. 2000 Aug 7;42(1084):70 |  Show IntroductionHide Introduction

Eflornithine Cream For Facial Hair Reduction

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2000  (Issue 1089)
. rhodesiense infections (Medical Letter Handbook of Antimicrobial Therapy, 2000, page 123). Nevertheless ...
Eflornithine hydrochloride cream 13.9% (Vaniqa - Bristol-Myers Squibb) has been approved by the FDA for reduction of unwanted facial hair in women.
Med Lett Drugs Ther. 2000 Oct 2;42(1089):96 |  Show IntroductionHide Introduction